Novo strikes up personalised diabetes treatment deal with Glooko

pharmafile | January 16, 2017 | News story | Sales and Marketing Glooko, Novo Nordisk, ibm 

Novo Nordisk has entered into a partnership with Californian firm Glooko to develop a number of offerings to aid with a range of issues affecting patients with type 1 and 2 diabetes including treatment adherence and blood glucose management.

These offerings will be integrated within Novo’s digital health platform developed with IBM Watson Health, a “virtual doctor” born from the company’s partnership with IBM signed in 2015.

“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” explained Christian Kanstrup, senior vice president, Strategy, Access & Marketing at Novo Nordisk. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

Glooko’s CEO Rick Altinger added: “Glooko’s partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier. We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world.”

Matt Fellows

Related Content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset …

Latest content